Severe Hypoglycemia from Helicobacter Pylori triple-drug therapy and insulin detemir drug interaction

Pharmacotherapy

Volumn 33, Issue 4, 2013, Pages

  Otsuka, Shelley H ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Drug interaction; H. pylori; Hypoglycemia; Insulin detemir; Triple drug therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; GLUCOSE; INSULIN ASPART; INSULIN DETEMIR; OMEPRAZOLE;

AGED; ANAMNESIS; ARTICLE; BEDTIME DOSAGE; CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HELICOBACTER INFECTION; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REPEATED DRUG DOSE;

AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; OMEPRAZOLE;

EID: 84879520781     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1228     Document Type: Article

References (22)

1. Go MF. Treatment and management of Helicobacter pylori infection. Curr Gastroenterol Rep 2002;4:471-477.
2. GlaxoSmithKline. Amoxil [package insert]. Research Triangle Park, NC; 2006.
3. Abbott Laboratories. Biaxin [package insert]. North Chicago, IL; 2012.
4. AstraZeneca Pharmaceutical. Prilosec [package insert]. Wilmington, DE; 2012.
5. Bussing R, Gende A. Severe hypoglycemia from clarithromycin- sulfonylurea drug interaction. Diabetes Care 2002;25: 1659-1661.
6. Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin- repaglinide drug interaction. Pharmacotherapy 2008;28:682-684.
7. Leiba A, Leibowitz A, Grossman E. An unusual case of hypoglycemia in a diabetic patient. Ann Emerg Med 2004;44:427-428.
8. Briscoe VJ, Davis S. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes 2006;24:115-121.
9. Fowler MJ. Hypoglycemia. Clin Diabetes 2008;26:170-173.
10. Holman RR, Thorne KI, Farmer AJ, et al. Addition of bi-phasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
11. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274.
12. McMahon GT, Dluhy RG. Intention to treat-initiating insulin and the 4-T study. N Engl J Med 2007;357:1759-1761.
13. Mathieu C. Can we reduce hypoglycaemia with insulin detemir? Int J Obes Relat Metab Disord 2004;28(Suppl 2):S35-S40.
14. Novo Nordisk Inc. Levemir [package insert]. Princeton, NJ; 2007.
15. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38:243-270.
16. Ebadi M. Desk referecnce of clinical pharmacology, 2nd ed. Boca Raton, FL: CRC Press; 2008.
17. Meyer A. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 1996;69:203-209.
18. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999;66:265-274.
19. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995;39: 2078-2083.
20. Pommerien W, Braun M, Idström JP, Wrangstadh M, Londong W. Pharmacokinetic and pharmacodynamics interactions between omeprazole and amoxicillin in Helicobacter pylori-positive subjects. Aliment Pharmacol Ther 1996;10: 295-301.
21. Murad MH, Coto-Yglesias F, Wang AT, et al. Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009;94:741-745.
22. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.